HCM
SGMT icon

Hollencrest Capital Management’s Sagimet Biosciences SGMT Stock Holding History

Hollencrest Capital Management’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-15
Closed -$114 – 1210
2025
Q2 		$114 Hold
15
– – ﹤0.01% 1103
2025
Q1 		$49 Buy
+15
New +$63 ﹤0.01% 1103

Other funds holding SGMT

WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Hollencrest Capital Management's SGMT Position: Q3 2025 in Review

Hollencrest Capital Management sold out of Sagimet Biosciences (SGMT) in Q3 2025, closing a stake of 15 shares — an estimated $114 sold.

Hollencrest Capital Management first reported a position in SGMT in Q1 2025 and held it in 2 quarters. The position peaked at $114 in Q2 2025. 72 funds tracked by Wall St. Rank hold SGMT as of Q3 2025.

  • Hollencrest Capital Management reported no remaining Sagimet Biosciences position as of Q3 2025 after selling out during the quarter.
  • Hollencrest Capital Management sold 15 Sagimet Biosciences shares in Q3 2025, an estimated $114.
  • Hollencrest Capital Management first reported a position in Sagimet Biosciences in Q1 2025 and held it in 2 quarters.
  • Hollencrest Capital Management's Sagimet Biosciences position peaked at $114 in Q2 2025.
  • 72 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q3 2025.

Based on Hollencrest Capital Management's 13F filing for Q3 2025, filed 3 Nov 2025.